LYNOZYFIC™ / linvoseltamab-gcpt
Implementation Package
Subscription Information
The purpose of this Implementation Package is to collect information that will assist us in configuring your product subscription on FormularyDecisions®.
As you complete the necessary information, your work is automatically saved so you can return to the Implementation Package at a later time. Please note that the completion of this Implementation Package is required in order to configure your product subscription.
If you notice a discrepancy in the information below, please reach out to Support@FormularyDecisions.com to have it corrected before you complete the package.
*This form is best suited for desktop and tablet devices.
Regeneron Pharmaceuticals
LYNOZYFIC™
linvoseltamab-gcpt
5/1/25
4/30/26
Laurie Ruelas
laurie.ruelas@regeneron.com
